Kathryn Hitchcock, MD
Radiation Oncology · Gainesville, FLNPI 1912267808
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $3,900 of the $5,708 with a category attached, or 68.3%. Telix Pharmaceuticals accounts for 71.0% of it on its own, with 3 other manufacturers making up the rest. 2025 is the largest year on record at $4,050, 2.5 times the $1,594 reported in 2019.
Across 18 payments — averaging $317.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Telix Pharmaceuticals$4K
- Merck$2K
- Elekta, Inc.$47
- Medtronic$17
Across 35 payments — averaging $14,244 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$498K
- Novartis$158
What the payments were for
- Consulting fees$3,90068%
- Travel & lodging$1,26622%
- Food & beverage$5429%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Telix Pharmaceuticals | 3 | $4,050 |
| Merck | 12 | $1,594 |
| Elekta, Inc. | 2 | $47 |
| Medtronic | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,708 in reported general payments places this provider in the 80th percentile of 465 radiation oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Morphine Sulfate ErMorphine Sulfate | 13 | $419 |
| Oxycodone Hcl | 15 | $294 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Gainesville
- Shravan KandulaOrlando$444K
- Martin KeischMiami Shores$319K
- Marcio FagundesMiami$274K
- Evan ThomasWinter Park$209K
- Rupesh KotechaMiami$208K
- John SylvesterLakewood Ranch$205K
- Ravi ShridharOrlando$192K
- Alan BrownFort Myers$165K
- Akash NandaOrlando$165K
- Michael ChuongMiami$152K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.